Article
ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC.
Cancer cell - 13 Sept 2021
Le Xiuning, Nilsson Monique B, Robichaux Jacqulyne P, Heymach John V
Abstract excerpt
The randomized ARTEMIS study demonstrates that adding the VEGF inhibitor bevacizumab to the EGFR inhibitor erlotinib improves progression-free survival in EGFR mutant non-small-cell lung cancer by more than 6 months, with even greater benefits seen in patients with brain metastases and EGFR L858R mutation. This provides further evidence for the tailored use of VEGF/EGFR combinations.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.